No profile data available.
Moleculin Biotech, Inc. (MBRX) is a healthcare company in the additional cancer treatment drugs industry, based in Houston, United States, with about 17 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$33.66 million. Its market capitalization was $9.01 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
Moleculin Biotech reported $0 in revenue for fiscal year 2025.
$9.01 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Phio Pharmaceuticals Corp. (PHIO), Bolt Biotherapeutics, Inc. (BOLT), Oncotelic Therapeutics, Inc. (OTLC), CNS Pharmaceuticals, Inc. (CNSP).